Methylene blue and Alzheimer's disease.

The relationship between methylene blue (MB) and Alzheimer's disease (AD) has recently attracted increasing scientific attention since it has been suggested that MB may slow down the progression of this disease. In fact, MB, in addition to its well characterized inhibitory actions on the cGMP pathway, affects numerous cellular and molecular events closely related to the progression of AD. Currently, MB has been shown to attenuate the formations of amyloid plaques and neurofibrillary tangles, and to partially repair impairments in mitochondrial function and cellular metabolism. Furthermore, various neurotransmitter systems (cholinergic, serotonergic and glutamatergic), believed to play important roles in the pathogenesis of AD and other cognitive disorders, are also influenced by MB. Recent studies suggest that the combination of diverse actions of MB on these cellular functions is likely to mediate potential beneficial effects of MB. This has lead to attempts to develop novel MB-based treatment modalities for AD. In this review article, actions of MB on neurotransmitter systems and multiple cellular and molecular targets are summarized with regard to their relevance to AD.

[1]  F. Gonzalez-Lima,et al.  Methylene blue prevents neurodegeneration caused by rotenone in the retina , 2009, Neurotoxicity Research.

[2]  J. Cragan.  Teratogen update: methylene blue. , 1999, Teratology.

[3]  T. Gura.  Hope in Alzheimer's fight emerges from unexpected places , 2008, Nature Network Boston.

[4]  Vildan Alptüzün,et al.  Targeting acetylcholinesterase to treat neurodegeneration , 2007, Expert opinion on therapeutic targets.

[5]  Takeshi Iwatsubo,et al.  Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins* , 2005, Journal of Biological Chemistry.

[6]  M. Wainwright,et al.  Methylene Blue - a Therapeutic Dye for All Seasons? , 2002, Journal of chemotherapy.

[7]  C. Dawson,et al.  Reduction and accumulation of methylene blue by the lung. , 1994, Journal of applied physiology.

[8]  R. Thomas,et al.  Methylene blue in treatment of bipolar illness , 1985, Biological Psychiatry.

[9]  L. Cincotta,et al.  Factors Affecting Virus Photoinactivation by a Series of Phenothiazine Dyes , 1998, Photochemistry and photobiology.

[10]  J. Wagner,et al.  Pharmacokinetics of highly ionized drugs. II. Methylene blue--absorption, metabolism, and excretion in man and dog after oral administration. , 1972, Journal of pharmaceutical sciences.

[11]  G. Naylor,et al.  Methylene blue. A possible treatment for manic depressive psychosis. , 1983, Journal of affective disorders.

[12]  D. Yew,et al.  Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients , 2006, BMC Neuroscience.

[13]  S. Standiford,et al.  Methylene-blue-associated encephalopathy. , 2007, Journal of the American College of Surgeons.

[14]  G. Petroianu,et al.  Entry of oximes into the brain: a review. , 2008, Current medicinal chemistry.

[15]  S. Paul,et al.  7-Nitroindazole and Methylene Blue, Inhibitors of Neuronal Nitric Oxide Synthase and NO-Stimulated Guanylate Cyclase, Block MK-801-Elicited Behaviors in Mice , 1996, Neuropsychopharmacology.

[16]  G. Riedel,et al.  Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine , 2008, Psychopharmacology.

[17]  C. Geula,et al.  Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. , 2004, Drugs of today.

[18]  C. Babbs,et al.  Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. A potential new drug for the attenuation of ischemia/reperfusion injury. , 1991, Biochemical pharmacology.

[19]  G. Burrows.  Methylene blue: effects and disposition in sheep. , 1984, Journal of veterinary pharmacology and therapeutics.

[20]  Ryan Walsh,et al.  Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. , 2007, Bioorganic & medicinal chemistry.

[21]  O. Müller,et al.  Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria , 2004, European Journal of Clinical Pharmacology.

[22]  M. Roth,et al.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  N. Inestrosa,et al.  Amyloid–cholinesterase interactions , 2008, The FEBS journal.

[24]  R. Fischmeister,et al.  Methylene blue is a muscarinic antagonist in cardiac myocytes. , 1997, Molecular pharmacology.

[25]  F Gonzalez-Lima,et al.  Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. , 2005, European journal of pharmacology.

[26]  Michael Shannon,et al.  The serotonin syndrome. , 2005, The New England journal of medicine.

[27]  M. Wainwright.  The use of dyes in modern biomedicine , 2003, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[28]  L. Breydo,et al.  Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. , 2007, Biochemistry.

[29]  D. Fung,et al.  Dyed but not dead--methylene blue overdose. , 1976, Anesthesiology.

[30]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[31]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[32]  D. Muller,et al.  Adverse Effects of Methylene Blue on the Central Nervous System , 2008, Anesthesiology.

[33]  P Taylor,et al.  Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. , 1993, Biochemistry.

[34]  T. Müller.  Methylene blue supravital staining: an evaluation of its applicability to the mammalian brain and pineal gland. , 1998, Histology and histopathology.

[35]  Ozden Tacal,et al.  Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. , 2008, Archives of biochemistry and biophysics.

[36]  M. Pfaffendorf,et al.  The interaction between methylene blue and the cholinergic system , 1997, British journal of pharmacology.

[37]  T. Küçükkılınç,et al.  Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes. , 2007, Archives of biochemistry and biophysics.

[38]  A. Nordberg.  Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[39]  G. Naylor,et al.  Methylene blue in mania , 1988, Biological Psychiatry.

[40]  G. Naylor,et al.  A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manicdepressive psychosis , 1986, Biological Psychiatry.

[41]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  F. Gonzalez-Lima,et al.  Methylene blue improves brain oxidative metabolism and memory retention in rats , 2004, Pharmacology Biochemistry and Behavior.

[43]  J. Stucki,et al.  Stimulation of respiration by methylene blue in rat liver mitochondria , 1997, FEBS letters.

[44]  T. Arendt,et al.  The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease , 2006, Journal of Neural Transmission.

[45]  T. Dandekar,et al.  Interactions of Methylene Blue with Human Disulfide Reductases and Their Orthologues from Plasmodium falciparum , 2007, Antimicrobial Agents and Chemotherapy.

[46]  Kristiansen Je.  Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich. , 1989 .

[47]  G. Wegener,et al.  Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo , 2000, British journal of pharmacology.

[48]  J. Heavner,et al.  Permeability of the blood-milk barrier to methylene blue in cows and goats. , 1984, Journal of veterinary pharmacology and therapeutics.

[49]  David L. McCollum,et al.  The brain metabolic enhancer methylene blue improves discrimination learning in rats , 2007, Pharmacology Biochemistry and Behavior.

[50]  F Gonzalez-Lima,et al.  Extinction memory improvement by the metabolic enhancer methylene blue. , 2004, Learning & memory.

[51]  A. Peters,et al.  Experiments on Vital Staining with Methylene Blue , 1953 .

[52]  B. Wermuth,et al.  Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue , 1994, The Lancet.

[53]  M. Kelner,et al.  Potential of methylene blue to block oxygen radical generation in reperfusion injury. , 1988, Basic life sciences.

[54]  M. Herman,et al.  Methylene blue by intraosseous infusion for methemoglobinemia. , 1999, Annals of emergency medicine.

[55]  D. Praticò.  Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. , 2008, Trends in pharmacological sciences.

[56]  James L. McGaugh,et al.  Methylene blue alters retention of inhibitory avoidance responses , 1978 .

[57]  C. Dees,et al.  Inactivation of the scrapie agent by ultraviolet irradiation in the presence of chlorpromazine. , 1985, The Journal of general virology.

[58]  B. Ng,et al.  Methylene blue is a potent monoamine oxidase inhibitor , 2008, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[59]  J. Parlow,et al.  The methylene blues: anticipating adverse reactions to non-anesthetic drugs , 2008, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[60]  R. Baldessarini,et al.  Neurosyphilis, Malaria, and the Discovery of Antipsychotic Agents , 2008, Harvard review of psychiatry.

[61]  P. Gillman.  Methylene blue implicated in potentially fatal serotonin toxicity , 2006, Anaesthesia.

[62]  J. Engel,et al.  Phencyclidine-induced behaviour in mice prevented by methylene blue. , 2004, Basic & clinical pharmacology & toxicology.

[63]  Kathleen A. Boyle,et al.  Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  R. Mcdonald,et al.  Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives. , 2005, Bioorganic & medicinal chemistry.

[65]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[66]  J. Watanabe,et al.  Dose dependency of apparent volumes of distribution for methylene blue in rabbits. , 1981, Journal of pharmacobio-dynamics.

[67]  G. Oxenkrug,et al.  Effect of Methylene Blue and Related Redox Dyes on Monoamine Oxidase Activity; Rat Pineal Content of N‐Acetylserotonin, Melatonin, and Related Indoles; and Righting Reflex in Melatonin‐Primed Frogs , 2007, Annals of the New York Academy of Sciences.

[68]  B. Lauterburg,et al.  Pharmacokinetics and organ distribution of intravenous and oral methylene blue , 2000, European Journal of Clinical Pharmacology.

[69]  K. Tomoo,et al.  Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. , 2008, Biochemical and biophysical research communications.

[70]  A. Khavandi,et al.  Serotonin toxicity precipitated by concomitant use of citalopram and methylene blue , 2008, The Medical journal of Australia.

[71]  C. Albright,et al.  Therapeutic Strategies for Alzheimer’s Disease , 2008, Molecular Neurobiology.

[72]  T. Cerny,et al.  Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[73]  P. Bentham,et al.  O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks , 2008, Alzheimer's & Dementia.

[74]  I. Fridovich,et al.  Intracellular production of superoxide radical and of hydrogen peroxide by redox active compounds. , 1979, Archives of biochemistry and biophysics.

[75]  P. Gillman,et al.  Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction , 2007, British journal of pharmacology.

[76]  I. Walter‐Sack,et al.  High absolute bioavailability of methylene blue given as an aqueous oral formulation , 2009, European Journal of Clinical Pharmacology.